Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An annual campaign to increase awareness of the disease.
Compared with chemotherapy alone, adding immunotherapy drug Keytruda helped triple-negative breast cancer patients live longer.
Triple Negative Breast Cancer Day is only global event dedicated to triple negative breast cancer.
The new cancer subtypes help better characterize a person’s tumor. The goal is to get the right drug to the right patient.
A cancer survivor turned health justice activist who helps other people with cancer navigate the confusing medical system
A look at the symptoms, treatments, risk factors, prognosis and research on breast cancer metastasis to the brain.
A novel clinical trial based on research from Cleveland Clinic’s Lerner Research Institute targets triple-negative breast cancer.
An estrogen receptor known as ERα plays a critical role in more than 70% of breast cancers.
The Food and Drug Administration recently approved the checkpoint inhibitor Keytruda (pembrolizumab).
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Overall survival increased by 30% among women with aggressive breast cancer who began statin use post-diagnosis.
This is the first immunotherapy approved for previously untreated triple-negative breast cancer that is likely to relapse.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.